A Phase I/II Evaluation of Stavudine (d4T) in Children With Human Immunodeficiency Virus Infection

Abstract

Stavudine appears to hold promise for the treatment of HIV infection in children. Its pharmacokinetic properties are consistent and predictable, and it appears to be remarkably well-tolerated and safe. Although our study was not designed to assess the drug's efficacy, preliminary clinical and laboratory evidence of activity was observed.